Business
Dover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19.
Expert Systems Inc., a leading life sciences accelerator, announced its continued support for Traws Pharma (NASDAQ: TRAW) as the company initiates Phase 2 clinical studies of Ratutrelvir (TRX01), a next-generation oral antiviral designed to treat newly diagnosed COVID-19 patients.
About this update from Traws Pharma, Inc.
[{"type":"text","content":"DOVER, Del., Oct. 22, 2025 /PRNewswire/ -- Expert Systems Inc., a leading life sciences accelerator, announced its continued support for Traws Pharma (NASDAQ: TRAW) as the company initiates Phase 2 clinical studies of Ratutrelvir (TRX01), a next-generation oral antiviral designed to treat newly diagnosed COVID-19 patients.","length":324,"tagName":"p"},{"type":"image","alt":"Expert Systems Inc - Taking drug discovery to the next level. (PRNewsfoto/Expert Systems, Inc.)","displaySize":"","headline":null,"caption":"Expert Systems Inc - Taking drug discovery to the next level. (PRNewsfoto/Expert Systems, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":200,"url":"https://media.zenfs.com/en/prnewswire.com/f09b46169e915fe48e569b05c647f5ad"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Y0apOY26rZcNX3GYoMoHOg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM1MztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/f09b46169e915fe48e569b05c647f5ad","width":400,"height":200}},"href":"https://mma.prnewswire.com/media/2595775/Expert_Systems_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Expert Systems' predictive pharmacology and AI-driven molecular modeling played a central role in Ratutrelvir's differentiation—optimizing pharmacokinetics, safety, and potency profiles to ensure broad clinical applicability across both therapeutic and preventive settings.","length":281,"tagName":"p"},{"type":"text","content":"Ratutrelvir (TRX01) demonstrates broad-spectrum in vitro activity against a range of SARS-CoV-2 virus strains and maintains exceptional potency profiles without requiring ritonavir co-administration. Its ritonavir-independent formulation eliminates the need for metabolic boosting, avoiding the ritonavir-associated drug-drug interactions that currently exclude approximately 20% of COVID patients from protease inhibitor treatment.","length":432,"tagName":"p"},{"type":"text","content":"In Phase 1 multiple ascending dose (MAD) studies, a daily oral 600 mg regimen sustained plasma concentrations ~13× above EC50 for the full 10-day course, with trough levels remaining above EC90 - critical for preventing viral rebound. Expert Systems' modeling predicts even higher concentrations in lung tissue versus plasma, enhancing antiviral exposure at the primary infection site.....